Goku has taken some wicked lives, the likes of which stand out even more because they’re so few and far between in Dragon ...

Goku's Ultra Instinct is his strongest form, and it completes his character in a way many fans may not suspect.

Dragon Ball Daima's finale didn't explain a major question, but it may have an answer. Read on to find out more ...

NASDAQ MRUS opened at $47.09 on Friday. The stock has a fifty day simple moving average of $42.04 and a 200-day simple moving average of $46.77. Merus has a twelve month low of $37.77 and a twelve ...

Kourtnee covers TV streaming services and home entertainment news and reviews at CNET. She previously worked as an entertainment reporter at Showbiz Cheat Sheet where she wrote about film ...

'Dragon,' starring Pradeep Ranganathan, is performing well at the box office. The movie has earned over Rs 45.70 crore in six days. Directed by Ashwath Marimuthu, the film has a strong presence ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Iovance Biotherapeutics (IOVA – Research Report), Xencor (XNCR – Research Report) and Merus ...

In September 2024, Merus announced the first patient was dosed in LiGeR-HN1, a phase 3 trial evaluating the efficacy and safety of petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC ...

Merus B.V. earnings at a glance (GAAP) : -Earnings: -$215.33 Mln. vs. -$154.94 Mln. last year. -EPS: -$3.35 vs. -$3.00 last year. -Revenue: $36.13 Mln vs. $43.95 Mln last year. The views and ...

Merus N.V. announced progress on its clinical trials involving petosemtamab, designed for treating recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal ...